Jeffrey V. Poulton Sells 1,605 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Free Report) CFO Jeffrey V. Poulton sold 1,605 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total transaction of $370,755.00. Following the completion of the sale, the chief financial officer now owns 28,892 shares of the company’s stock, valued at approximately $6,674,052. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $247.00 on Friday. The company has a market capitalization of $31.24 billion, a P/E ratio of -92.16 and a beta of 0.30. The business has a fifty day simple moving average of $157.89 and a two-hundred day simple moving average of $164.23. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter last year, the firm posted ($1.40) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.75 earnings per share for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Teachers Retirement System of The State of Kentucky boosted its position in shares of Alnylam Pharmaceuticals by 8.1% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock valued at $4,964,000 after acquiring an additional 2,500 shares during the last quarter. Cetera Advisors LLC purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth approximately $238,000. Burney Co. increased its holdings in shares of Alnylam Pharmaceuticals by 371.9% in the 1st quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 21,325 shares during the last quarter. Swedbank AB purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $3,084,000. Finally, Plato Investment Management Ltd grew its position in Alnylam Pharmaceuticals by 2,666.3% in the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 4,346 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALNY. Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an “overweight” rating in a report on Tuesday. Evercore ISI raised their price objective on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday. Canaccord Genuity Group reiterated a “buy” rating and issued a $283.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, June 21st. Finally, Bank of America boosted their price target on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the company a “buy” rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $245.14.

Read Our Latest Analysis on Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Recommended Stories

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.